December 05, 2020

Read for 2 minutes

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

Healio and Cardiology Today have rounded up the most-read news from the American Heart Association’s virtual science sessions.

Readers were interested in the CV effects of omega-3 fatty acids and vitamin D supplementation; the results of the GALACTIC-HF study with Omecamtiv Mecarbil (Amgen / Cytokinetics / Servier) in HF; the effect of high-dose vs. low-dose influenza vaccine on CVD prevention in high-risk patients; and more.

Source: Adobe Stock

No use of daily omega-3 and vitamin D supplements to prevent atrial fibrillation

Taking omega-3 fatty acids and vitamin D3 supplements did not increase or decrease the risk of atrial fibrillation over 5 years, according to the results of the VITAL Rhythm study. Continue reading

Fauci: The underlying cardiovascular disease increases the risk for COVID-19 severity and death

COVID-19 can cause severe cardiovascular complications that manifest themselves in arrhythmias, myocardial injuries, thromboembolic phenomena, and cardiomyopathies, said Anthony S. Fauci, MD, during a presentation at the American Heart Association’s Scientific Sessions. Continue reading

STRENGTH: No CV advantage with omega-3 carboxylic acid

Administration of high-dose omega-3 carboxylic acid compared to corn oil placebo did not reduce the incidence of serious adverse cardiovascular events in statin-treated adults with elevated triglycerides and high cardiovascular risk. Continue reading

INVESTED: High-dose influenza vaccine does not reduce deaths and cardiovascular events in high-risk cohort

According to the results of the INVESTED study, injection of a high-dose influenza vaccine had no effect on all-cause death, cardiac or lung hospitalization compared to a lower dose in patients with previous myocardial infarction or HF hospitalization. Continue reading

Omecamtiv mecarbil lowers cardiovascular deaths / HF events in HFrEF: GALACTIC-HF

According to the results of the GALACTIC-HF study, Omecamtiv mecarbil, a novel selective cardiac myosin activator, was associated with an 8 percent reduction in cardiovascular death or first HF events in patients with HF with a reduced ejection fraction. Continue reading

AHA issues call to action to combat systemic racism in the United States

In a recommendation from the President of the American Heart Association, the association called for action and called for steps to be taken to address structural racism as a cause of health inequalities. Continue reading

The COVID-19 CVD registry highlights racial / ethnic inequalities and the risk of obesity

CVD complications in patients with COVID-19 are less common than expected, but COVID-19 complications disproportionately affect obese patients as well as black and Hispanic people, according to new registry data. Continue reading

Daily polypill plus aspirin lowers the risk of cardiovascular disease and death

Intermediate cardiovascular risk adults given a polypill plus aspirin were 31% less likely to have a cardiovascular event or death compared to those given a double placebo, according to new data from the TIPS-3 study has been. Continue reading

Results of the ISCHEMIA study consistent by CTO status

Among the patients with stable ischemic heart disease enrolled in the ISCHEMIA study, those with chronic total occlusion lesions had similar results to those who did not. Continue reading

Cannabis use can lead to increased approval for acute myocardial infarction, poorer results for PCI

Cannabis use is increasing in the US, and although users are typically younger, their risk of acute myocardial infarction is increased, and post-PCI cannabis users may be at increased risk of bleeding and stroke compared to non-users, researchers reported. Continue reading

Iron supplementation for deficiency in acute HF lowers the risk of future hospitalization

According to the results of the AFFIRM-AHF study, supplementation in patients with iron deficiency who were hospitalized with acute HF reduced the subsequent HF hospital stay by approx

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

American Heart Association

American Heart Association

LEAVE A REPLY

Please enter your comment!
Please enter your name here